Hypertrophic cardiomyopathy: prevalence of disease-specific red flags

被引:0
|
作者
Maurizi, Niccolo [1 ,2 ,3 ]
Monda, Emanuele [4 ]
Biagini, Elena [5 ]
Field, Ella [6 ,7 ]
Passantino, Silvia [8 ]
Dall' Aglio, Gabriella [3 ]
Fumagalli, Carlo [3 ]
Antiochos, Panagiotis [1 ,2 ]
Skalidis, Ioannis [1 ,2 ]
Pieroni, Maurizio [9 ]
Argiro, Alessia [3 ]
Girolami, Francesca [8 ]
Cecchi, Franco
Barbey, Frederic [10 ]
Monney, Pierre [1 ,2 ]
Elliott, Perry M. [11 ,12 ]
Kaski, Juan Pablo [6 ,7 ]
Limongelli, Giuseppe [4 ]
Olivotto, Iacopo [3 ]
机构
[1] Univ Hosp Lausanne CHUV, Serv Cardiol, Dept Visceral Surg, Rue Bugnon 46,BH16, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne Unil, Rue Bugnon 46,BH16, CH-1011 Lausanne, Switzerland
[3] Careggi Univ Hosp, Cardiomyopathy Unit, I-50134 Florence, Italy
[4] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Inherited & Rare Cardiovasc Dis Unit, Naples, Italy
[5] IRCCS Azienda Osped Univ Bologna, Cardiol Unit, Bologna, Italy
[6] UCL, Ctr Paediat Inherited & Rare Cardiovasc Dis, Inst Cardiovasc Sci, London, England
[7] Great Ormond St Hosp Sick Children, Ctr Inherited Cardiovasc Dis, London, England
[8] Meyer Childrens Hosp IRCCS, Serv Cardiol, Florence, Italy
[9] San Donato Hosp, Cardiovasc Dept, Arezzo, Italy
[10] Lausanne Univ Hosp, Serv Immunol, Lausanne, Switzerland
[11] UCL, Inst Cardiol Sci, Ctr Heart Muscle Dis, London, England
[12] St Bartholomews Hosp, London, England
关键词
Hypertrophic cardiomyopathy; Phenocopies; Red flags; ANDERSON-FABRY DISEASE; DIAGNOSIS; MANAGEMENT; SOCIETY; ESC;
D O I
10.1093/eurheartj/ehaf026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or 'red flags' (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease management. To date, the prevalence and clinical significance of RF associated with HCM phenotypes in different clinical settings are unknown. Methods The study cohort comprised 818 patients with a clinical diagnosis of HCM [479 (62%) males, mean age 49 +/- 21 years] referred to four European centres. Pre-specified RFs were categorized into one of five domains: (i) family history; (ii) physical examination; (iii) electrocardiography; (iv) echocardiography; and (v) laboratory. Results A total of 318 (39%) patients had a pathogenic or likely pathogenic sarcomere gene variant; 240 (29%) a TTR and GLA variant; 154 (19%) a syndromic cause; and 106 (13%) no identifiable cause. In the overall cohort, 2979 RFs were identified. Of these, 1018 (34%) were identifiable from clinical history and examination alone (generalist setting) and 1961 (66%) by 12-lead electrocardiogram and echocardiography (cardiologist's office). Non-sarcomeric patients were diagnosed more often aged <20 and after 60 years (476/500, 95%). Syndromic diseases such as Rasopathies, inherited metabolic disorders, and mitochondrial disorders were diagnosed in neonatal/early childhood (mean age 3 +/- 2 years), whereas patients with Danon disease, Friedreich's ataxia, Noonan syndrome, and PRKAG2 cardiomyopathy were identified mostly during adolescence (mean age 16 +/- 8 years). Non-cardiac RFs identified by clinical history, physical examination, and routine laboratory testing were most frequent in patients with HCM caused by Rasopathies, inherited metabolic disorders, and mitochondrial disorders (48%, 47%, and 57%, respectively). Physical RFs were almost exclusively observed in patients with a definite non-sarcomeric aetiology [348/350 (99%)]. On the contrary, most RFs associated with geno-positive and geno-negative HCM were derived from electrocardiogram and echocardiography [692/990 (70%) and 332/375 (88%), respectively]. Conclusions Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Disease-specific prevalence of red flags for rare diseases in patients presenting with a Hypertrophic Cardiomyopathy phenotype
    Maurizi, Niccolo
    Monda, Emanuele
    Biagini, Elena
    Fumagalli, Carlo
    Cecchi, Franco
    Monney, Pierre
    Elliott, Perry
    Limongelli, Giuseppe
    Kasky, Juan Pablo
    Olivotto, Iacopo
    SWISS MEDICAL WEEKLY, 2023, 153 : 30S - 30S
  • [2] Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy
    Limongelli, Giuseppe
    Monda, Emanuele
    Tramonte, Stefania
    Gragnano, Felice
    Masarone, Daniele
    Frisso, Giulia
    Esposito, Augusto
    Gravino, Rita
    Ammendola, Ernesto
    Salerno, Gemma
    Rubino, Marta
    Caiazza, Martina
    Russo, Mariagiovanna
    Calabro, Paolo
    Elliott, Perry Mark
    Pacileo, Giuseppe
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 299 : 186 - 191
  • [3] Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy
    Monda, Emanuele
    Tramonte, Stefania
    Gragnano, Felice
    Masarone, Daniele
    Frisso, Giulia
    Esposito, Augusto
    Gravino, Rita
    Ammendola, Ernesto
    Salerno, Gemma
    Rubino, Marta
    Caiazza, Martina
    Russo, Maria Giovanna
    Calabro, Paolo
    Elliott, Perry Mark
    Pacileo, Giuseppe
    Limongelli, Giuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J186 - J186
  • [4] Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy
    Capilupi, Michael J.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2023, 31 (01) : 45 - 51
  • [5] Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy
    Pysz, Piotr
    Rajtar-Salwa, Renata
    Smolka, Grzegorz
    Olivotto, Iacopo
    Wojakowski, Wojciech
    Petkow-Dimitrow, Pawel
    KARDIOLOGIA POLSKA, 2021, 79 (09) : 949 - 954
  • [6] Disease-specific differences of left ventricular rotational mechanics between cardiac amyloidosis and hypertrophic cardiomyopathy
    Nucifora, Gaetano
    Muser, Daniele
    Morocutti, Giorgio
    Piccoli, Gianluca
    Zanuttini, Davide
    Gianfagna, Pasquale
    Proclemer, Alessandro
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2014, 307 (05): : H680 - H688
  • [7] Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy The Need for Disease-Specific Criteria
    Cappelli, Francesco
    Morini, Sofia
    Pieragnoli, Paolo
    Targetti, Mattia
    Stefano, Pierluigi
    Marchionni, Niccolo
    Olivotto, Iacopo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (04) : 464 - 466
  • [8] Prevalence of fabry disease in patients with hypertrophic cardiomyopathy
    Azevedo, O.
    Marques, N.
    Reis, L.
    Gomes, A.
    Abreu, L.
    Domingues, K.
    Santos, R.
    Leao, S.
    Picarra, B.
    Lima, R.
    Faria, R.
    Fonseca, C.
    Sousa, N.
    Cunha, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1152 - 1152
  • [9] Contemporary Surgical Management of Hypertrophic Cardiomyopathy, the Need for More Myectomy Surgeons and Disease-Specific Centers, and the Tufts Initiative
    Maron, Barry J.
    Rastegar, Hassan
    Udelson, James E.
    Dearani, Joseph A.
    Maron, Martin S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (09): : 1512 - 1515
  • [10] Prevalence of fabry disease in female patients with hypertrophic cardiomyopathy
    Chimenti, C
    Pieroni, M
    Morgante, E
    Verardo, R
    Antuzzi, D
    Russo, MA
    Maseri, A
    Frustaci, A
    EUROPEAN HEART JOURNAL, 2003, 24 : 561 - 561